...
首页> 外文期刊>Scientific reports. >Polymeric human Fc-fusion proteins with modified effector functions
【24h】

Polymeric human Fc-fusion proteins with modified effector functions

机译:具有修饰的效应子功能的聚合人Fc融合蛋白

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The success of Fc-fusion bio-therapeutics has spurred the development of other Fc-fusion products for treating and/or vaccinating against a range of diseases. We describe a method to modulate their function by converting them into well-defined stable polymers. This strategy resulted in cylindrical hexameric structures revealed by tapping mode atomic force microscopy (AFM). Polymeric Fc-fusions were significantly less immunogenic than their dimeric or monomeric counterparts, a result partly owing to their reduced ability to interact with critical Fc-receptors. However, in the absence of the fusion partner, polymeric IgG1-Fc molecules were capable of binding selectively to FcγRs, with significantly increased affinity owing to their increased valency, suggesting that these reagents may prove of immediate utility in the development of well-defined replacements for intravenous immunoglobulin (IVIG) therapy. Overall, these findings establish an effective IgG Fc-fusion based polymeric platform with which the therapeutic and vaccination applications of Fc-fusion immune-complexes can now be explored.. ? 2011 Macmillan Publishers Limited. All rights reserved
机译:Fc融合生物疗法的成功推动了其他Fc融合产品的开发,这些产品可用于治疗和/或接种多种疾病。我们描述了一种通过将其转化为定义明确的稳定聚合物来调节其功能的方法。此策略导致通过敲击模式原子力显微镜(AFM)揭示圆柱形六聚体结构。聚合Fc融合体的免疫原性明显低于其二聚体或单体对应体,其部分原因是其与关键Fc受体相互作用的能力降低。但是,在没有融合伴侣的情况下,聚合的IgG1-Fc分子能够选择性地与FcγRs结合,由于它们的化合价增加,亲和力显着提高,这表明这些试剂可证明可立即用于明确定义的替代品的开发中。用于静脉内免疫球蛋白(IVIG)治疗。总体而言,这些发现建立了有效的基于IgG Fc融合的聚合物平台,现在可以利用该平台探索Fc融合免疫复合物的治疗和疫苗接种应用。 2011 Macmillan Publishers Limited。版权所有

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号